-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – THR-149
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry THR-149 Drug Details THR-149 is under development for treatment of diabetic macular edema associated...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – THR-687
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry THR-687 Drug Details THR-687 is under development for the treatment of proliferative diabetic retinopathy...
-
Product Insights
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
The Placenta Growth Factor pipeline drugs market research report outlays comprehensive information on the Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also reviews key players involved in Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics development with respective active and dormant or discontinued projects.
-
Product Insights
Non-Proliferative Diabetic Retinopathy (NPDR) Disease – Global Clinical Trials Review, H2 2020
GlobalData's clinical trial report, “Non-Proliferative Diabetic Retinopathy (NPDR) Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Non-Proliferative Diabetic Retinopathy (NPDR) Clinical trials scenario. This report provides top line data relating to the clinical trials on Non-Proliferative Diabetic Retinopathy (NPDR). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points...
-
Product Insights
Medulloblastoma Disease – Global Clinical Trials Review, H2, 2020
GlobalData's clinical trial report, “Medulloblastoma Global Clinical Trials Review, H2, 2020" provides an overview of Medulloblastoma Clinical trials scenario. This report provides top line data relating to the clinical trials on Medulloblastoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Sector Analysis
United States Cardiovascular Devices Market Outlook to 2025 – Aortic and Vascular Graft Devices, Atherectomy Devices, Cardiac Assist Devices and Others
GlobalData’s “United States Cardiovascular Devices Market Outlook to 2025” is a comprehensive databook report, covering key market data on the United States Cardiovascular Devices market. The databook report provides value (USD), volume (units) and average prices (USD) within market segments – Aortic and Vascular Graft Devices, Atherectomy Devices, Cardiac Assist Devices, Cardiac Rhythm Management Devices, Cardiovascular Prosthetic Devices, Cardiovascular Surgery Devices, Clot Management Devices, Electrophysiology Devices, Interventional Cardiology, Peripheral Vascular Devices and Prosthetic Heart Valves. The United States Cardiovascular Devices...